ADT + brexpiprazole

ADT + brexpiprazole is a combination therapy consisting of androgen deprivation therapy (ADT) and brexpiprazole. ADT refers to a class of treatments that reduce levels of male hormones (androgens), primarily testosterone, to slow or stop the growth of hormone-sensitive prostate cancer. This can be achieved through surgical castration (orchiectomy) or more commonly with medications such as luteinizing hormone-releasing hormone (LHRH) agonists or antagonists, and sometimes in combination with anti-androgens[8]. Brexpiprazole is an atypical antipsychotic classified as a serotonin–dopamine activity modulator; it acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors[1]. Brexpiprazole is approved for use in major depressive disorder (as adjunctive therapy), schizophrenia, and agitation associated with dementia due to Alzheimer’s disease[4][5]. The rationale for combining ADT with other agents in prostate cancer has been established for drugs like docetaxel or abiraterone, but there is no evidence supporting the clinical use of brexpiprazole in combination with ADT for any indication based on current literature. No trials or approvals exist for this specific drug pairing.